 |
市場調查報告書
商品編碼
1616769
門診腫瘤輸液市場機會、成長動力、產業趨勢分析及 2024 年至 2032 年預測Outpatient Oncology Infusion Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 to 2032 |
||||||
2023 年，全球門診腫瘤輸液市場估值為24 億美元。病率上升推動的，以及更廣泛的醫療保健政策和保險範圍。這種動態促進了向門診治療的過渡，因其成本效益和效率而受到稱讚。癌症仍然是一個緊迫的全球公共衛生挑戰，病例和死亡率的上升凸顯了這個挑戰。例如，美國癌症協會報告稱，2021 年美國約有 608,570 例癌症相關死亡。
這種巨大的癌症負擔擴大了對輸注療法和藥物輸注系統的需求，推動了市場成長。幾個關鍵趨勢正在塑造市場軌跡。這些包括不斷成長的老年人口以及在舒適性、成本效益和技術創新的推動下向門診設施的明顯轉變。此外，不斷發展的醫療保健政策和不斷上升的生存率將在預測期內提振市場。
整個產業分為產品、應用、療法、模式、區域。市面上的產品分為輸液幫浦、靜脈注射器、靜脈插管和無針連接器。輸液幫浦領域處於領先地位，2023 年收入達 12 億美元。輸液幫浦確保化療藥物的連續、受控輸送，最大限度地減少劑量錯誤並增強治療效果。
| 市場範圍 | |
|---|---|
| 開始年份 | 2023年 |
| 預測年份 | 2024-2032 |
| 起始值 | 24億美元 |
| 預測值 | 59 億美元 |
| 複合年成長率 | 10.6% |
門診腫瘤輸液市場的應用涵蓋肺癌、肝癌、乳癌、攝護腺癌等。 2023 年，乳癌以 20.5% 的市佔率領先。這種主導地位源於其全球流行、一系列先進的治療途徑、對門診護理的傾斜以及強大的患者支持機制。值得注意的是，《2022 年全球癌症統計》強調2022 年將新增230 萬名女性乳癌病例。 10%。公共衛生措施、篩檢進步和診斷技術進步在促進及時的癌症干預和治療方面進一步發揮了作用。
目錄
第 1 章：方法與範圍
第 2 章：執行摘要
第 3 章：產業洞察
- 產業生態系統分析
- 產業影響力
- 成長動力
- 輸液幫浦的最新技術進步
- 全球癌症盛行率上升
- 政府提高癌症意識的措施不斷湧現
- 產業陷阱與挑戰
- 癌症治療費用高昂
- 成長動力
- 成長潛力分析
- 監管環境
- 技術景觀
- 報銷場景
- 波特的分析
- PESTEL分析
- 未來市場趨勢
- 差距分析
第 4 章：競爭格局
- 介紹
- 公司矩陣分析
- 公司市佔率分析
- 競爭定位矩陣
- 戰略儀表板
第 5 章：市場估計與預測：按產品分類，2021 - 2032 年
- 主要趨勢
- 點滴幫浦
- 靜脈注射套
- 靜脈插管
- 無針頭連接器
第 6 章：市場估計與預測：按應用分類，2021 - 2032
- 主要趨勢
- 肺癌
- 肝癌
- 乳癌
- 攝護腺癌
- 其他癌症
第 7 章：市場估計與預測：按療法分類，2021 - 2032 年
- 主要趨勢
- 化療
- 標靶治療
- 免疫療法
- 荷爾蒙療法
第 8 章：市場估計與預測：按模式，2021 - 2032
- 主要趨勢
- 肌肉注射 (IM)
- 靜脈注射 (IV)
- 皮下
- 其他模式
第 9 章：市場估計與預測：按地區，2021 - 2032
- 主要趨勢
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
- 亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
- 中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區
第 10 章：公司簡介
- B. Braun Melsungen AG
- Baxter
- Becton, Dickinson, and Company
- Fresenius Kabi
- ICU Medical, Inc
- IRadimed Corporation
- Medtronic PLC
- Micrel Medical Devices SA
- Moog, Inc.
- Nipro Corporation
- Roche Diagnostics
- Smiths Medical
- Teleflex, Inc.
- Terumo Corporation
The Global Outpatient Oncology Infusion Market was valued at USD 2.4 billion in 2023. Projections indicate a growth trajectory, with an expected CAGR of 10.6% from 2024 to 2032. This robust market expansion is fueled by technological strides in infusion pumps, a rising cancer prevalence, and broader healthcare policies and insurance coverage. Such dynamics bolster the transition to outpatient treatments, lauded for their cost-effectiveness and efficiency. Cancer remains a pressing global public health challenge, underscored by rising cases and mortality rates. For instance, the American Cancer Society reported approximately 608,570 cancer-related deaths in the U.S. in 2021. Breast cancer topped the list with 284,200 new cases, followed by prostate and lung cancers.
This significant cancer burden amplifies the demand for infusion therapies and drug infusion systems, propelling the market growth. Several pivotal trends are shaping the market trajectory. These encompass a growing geriatric demographic and a pronounced shift towards outpatient facilities, driven by comfort, cost-effectiveness, and technological innovations. Moreover, evolving healthcare policies and rising survival rates are poised to bolster the market during the forecast period.
The overall industry is divided into product, application, therapy, mode, and region. The market categorizes products into infusion pumps, intravenous sets, IV cannulas, and needleless connectors. Leading the pack, the infusion pumps segment raked in USD 1.2 billion in revenue in 2023. Their rising adoption in outpatient cancer therapies is attributed to precise drug delivery, the capability to handle intricate chemotherapy regimens, and enhanced patient outcomes. Infusion pumps ensure continuous, controlled delivery of chemotherapeutic agents, minimizing dosage errors and amplifying treatment efficacy.
| Market Scope | |
|---|---|
| Start Year | 2023 |
| Forecast Year | 2024-2032 |
| Start Value | $2.4 Billion |
| Forecast Value | $5.9 Billion |
| CAGR | 10.6% |
Applications in the outpatient oncology infusion market span lung, liver, breast, prostate cancers, and others. In 2023, breast cancer led the charge with a 20.5% market share. This dominance stems from its global prevalence, a spectrum of advanced treatment avenues, a tilt towards outpatient care, and robust patient support mechanisms. Notably, Global Cancer Statistics 2022 highlighted 2.3 million new female breast cancer cases in 2022.North America, with a 2023 revenue of USD 1 billion, is set to grow at a CAGR of 10% from 2024 to 2032. The region's leadership is driven by a surge in cancer prevalence, underscoring the need for efficient treatment avenues like outpatient oncology infusions.A heightened cancer awareness, emphasizing early diagnosis, further cements North America's position. Public health initiatives, screening advancements, and diagnostic tech progress have further played roles in facilitating timely cancer interventions and treatments.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Recent technological advancements in infusion pumps
- 3.2.1.2 Rising prevalence of cancer across the globe
- 3.2.1.3 Surging government initiatives for cancer awareness
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 High costs of cancer therapies
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Technology landscape
- 3.6 Reimbursement scenario
- 3.7 Porter's analysis
- 3.8 PESTEL analysis
- 3.9 Future market trends
- 3.10 Gap analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Company market share analysis
- 4.4 Competitive positioning matrix
- 4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Infusion pumps
- 5.3 Intravenous sets
- 5.4 IV cannulas
- 5.5 Needleless connectors
Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Lung cancer
- 6.3 Liver cancer
- 6.4 Breast cancer
- 6.5 Prostate cancer
- 6.6 Other cancers
Chapter 7 Market Estimates and Forecast, By Therapy, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Chemotherapy
- 7.3 Targeted therapy
- 7.4 Immunotherapy
- 7.5 Hormonal therapy
Chapter 8 Market Estimates and Forecast, By Mode, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 Intramuscular (IM)
- 8.3 Intravenous (IV)
- 8.4 Subcutaneous
- 8.5 Other modes
Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
- 9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
- 10.1 B. Braun Melsungen AG
- 10.2 Baxter
- 10.3 Becton, Dickinson, and Company
- 10.4 Fresenius Kabi
- 10.5 ICU Medical, Inc
- 10.6 IRadimed Corporation
- 10.7 Medtronic PLC
- 10.8 Micrel Medical Devices SA
- 10.9 Moog, Inc.
- 10.10 Nipro Corporation
- 10.11 Roche Diagnostics
- 10.12 Smiths Medical
- 10.13 Teleflex, Inc.
- 10.14 Terumo Corporation
